Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb Co.

www.bms.com

Latest From Bristol-Myers Squibb Co.

Pionyr Maps Tumor Microenvironment, Plans 'Surgical' Strikes

Emerging Company Profile: Pionyr Immunotherapeutics exec who once led early development for Merck's PD-1 inhibitor Keytruda explains the San Francisco start-up's approach to rebalancing the tumor's microenvironment in order to improve outcomes.

StartUps and SMEs ImmunoOncology

EU Delays For Portola As CHMP Trend Votes Go Good And Bad

Portola will have to rein in its European sales ambitions as the CHMP gives early verdicts on its Factor Xa inhibitor betrixaban and its reversal agent andexanet. 

Approvals Policy & Regulation

Think Positive: Clovis Confident Of CHMP Okay For Rubraca

The US biotech expects to finally get its PARP inhibitor for ovarian cancer onto the European market in the next few months to compete with rivals AstraZeneca and Tesaro after the CHMP "communicated a positive trend vote" ahead of an opinion being issued next month.

Cancer Drug Review

Merck & Co's Viralytics Buy Puts Oncolytic Viruses Back In Spotlight

The US major is spending $394m to get hold of Cavatak, an immunotherapy that it hopes will work well in combination with the anti-PD-1 blockbuster Keytruda.

ImmunoOncology M & A
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register